Company intelligence / Profile preview

Foundation Actigenomics

Geneva, Geneva, Switzerland

Ownership: Private
Development stage: Other

Overview

Actigenomics was a Swiss biotechnology company focused on the discovery and development of small molecule drugs targeting nuclear receptors for metabolic and inflammatory diseases. The company utilized a proprietary platform to identify selective modulators of nuclear receptors, aiming to treat conditions such as obesity, type 2 diabetes, and dyslipidemia. Founded as a spin-off from the Institute of Genetics and Molecular and Cellular Biology (IGBMC), it sought to leverage high-throughput screening and genomic technologies. However, the company is no longer active, having ceased operations several years ago.

Therapeutic areas: EndocrinologyCardiovascularMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Foundation Actigenomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Foundation Actigenomics.

Explore the full profile